Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2024 Jan 4;30(3):906. doi: 10.1038/s41591-023-02775-w

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John M Kirkwood 1,, Michele Del Vecchio 2, Jeffrey Weber 3, Christoph Hoeller 4, Jean-Jacques Grob 5, Peter Mohr 6, Carmen Loquai 7, Caroline Dutriaux 8, Vanna Chiarion-Sileni 9, Jacek Mackiewicz 10, Piotr Rutkowski 11, Petr Arenberger 12, Gaelle Quereux 13, Tarek M Meniawy 14, Paolo A Ascierto 15, Alexander M Menzies 16, Piyush Durani 17, Maurice Lobo 17, Federico Campigotto 17, Brian Gastman 18,#, Georgina V Long 16,#
PMCID: PMC10957465  PMID: 38177857

Correction to: Nature Medicine 10.1038/s41591-023-02583-2, published online 16 October 2023.

In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank P”. This has now been corrected in the HTML and PDF versions of the article.


Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES